Spyre Therapeutics
Yahoo Finance • 23 days ago
Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum
WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational t... Full story
Yahoo Finance • 26 days ago
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational th... Full story
Yahoo Finance • 2 months ago
The Math Shows SCHA Can Go To $31
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story
Yahoo Finance • 2 months ago
Spyre Therapeutics GAAP EPS of -$0.49 beats by $0.28
* Spyre Therapeutics press release [https://seekingalpha.com/pr/20190026-spyre-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate] (NASDAQ:SYRE [https://seekingalpha.com/symbol/SYRE]): Q2 GAAP EPS of -$0.49... Full story
Yahoo Finance • 2 months ago
Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Reported positive interim Phase 1 results for two next-generation TL1A antibodies, demonstrating both were well-tolerated, exhibited pharmacokinetic ("PK") profiles supporting quarterly or biannual dosing, and full TL1A engagement through... Full story
Yahoo Finance • 3 months ago
Spyre reports results from early stage TL1A antibody trials
[3d illustration proteins] Design Cells/iStock via Getty Images * Spyre Therapeutics (NASDAQ:SYRE [https://seekingalpha.com/symbol/SYRE]) reported updates from its initial early stage studies involving SPY002 and SPY072, the company's n... Full story
Yahoo Finance • 3 months ago
Spyre reports positive results for anti-TL1A antibodies in trials
WALTHAM, Mass. - Spyre Therapeutics (NASDAQ:SYRE), a clinical-stage biotech company currently valued at $1.04 billion, announced positive interim Phase 1 results for its investigational extended half-life monoclonal antibodies SPY002 and S... Full story
